Enanta Pharmaceuticals (ENTA) Upgraded by Zacks Investment Research to Buy

Enanta Pharmaceuticals} stock has undergone multiple analysts rating changes in the recent past.  Enanta Pharmaceuticals Upgraded by Zacks Investment Research on 10-11-21. In a note to investors, the firm issued a new rating of Buy. The analysts previously had rating of Hold.

View More Enanta Pharmaceuticals (ENTA) Upgraded by Zacks Investment Research to Buy